CN1431016A - 调节血糖、血脂保健食品的组成及其制备方法 - Google Patents
调节血糖、血脂保健食品的组成及其制备方法 Download PDFInfo
- Publication number
- CN1431016A CN1431016A CN 03114899 CN03114899A CN1431016A CN 1431016 A CN1431016 A CN 1431016A CN 03114899 CN03114899 CN 03114899 CN 03114899 A CN03114899 A CN 03114899A CN 1431016 A CN1431016 A CN 1431016A
- Authority
- CN
- China
- Prior art keywords
- blood sugar
- health food
- water
- fat
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 24
- 210000004369 blood Anatomy 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims description 5
- 235000013305 food Nutrition 0.000 title abstract description 3
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 230000036541 health Effects 0.000 title description 13
- 238000000034 method Methods 0.000 title description 6
- 230000000694 effects Effects 0.000 claims abstract description 16
- 241001122767 Theaceae Species 0.000 claims abstract description 11
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 6
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 6
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 4
- 239000011573 trace mineral Substances 0.000 claims abstract description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000013402 health food Nutrition 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 108010064851 Plant Proteins Proteins 0.000 abstract 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 235000021118 plant-derived protein Nutrition 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- -1 flavanol compound Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明是一种调节血糖、血脂保健食品的配方组成及其制备方法。它是以从提取过茶多酚的下脚料中提取的茶多糖(含部分小分子低聚糖)、茶多酚、植物蛋白、微量元素为主要原料。经过保健食品法定机构的毒理试验和功能试验证明,对高血糖、高血脂有明显调节作用,是一种高效、迅速、剂量小、纯天然、服用方便的防治高血糖和高血糖的保健食品。
Description
技术领域
本发明涉及一种调节血糖、血脂保健食品的组成及其制备方法。
背景技术
目前对于糖尿病的治疗,通常是采用注射胰岛素及口服磺酰脲类和双胍类口服药。磺酰脲类药物对幼年型和重度糖尿病患者疗效差,且剂量稍有不慎容易引起过敏反应,如恶心、食欲不振等;双胍类药物亦有明显的胃肠刺激症状。对于注射胰岛素类药物用量不当易引起低血糖反应,出现昏迷、心悸、手抖无力等症状;还易引起患者对药物的依赖型,其疗效也不是很好。
茶多糖是从茶叶中提取出来,由葡萄糖、***糖、核糖、木糖、半乳糖、岩藻糖等单糖组成的天然高分子化合物,分子量约为4×104道尔顿,同茶叶中一些小分子低聚糖一起具有降血糖、降血脂、增强免疫力、抗动脉粥样硬化、抗凝血、抗血栓的作用,早在10多年前在日本就有以茶多糖为主要成分的保健食品上市。茶多酚是一种从茶叶中提取出来的纯天然抗氧剂,含有儿茶素、花青素、黄烷醇类、花色柑、黄酮醇类和酚酸类等6种活性成分,具有抗菌、抗癌、抗衰老、抗紫外线和消除自由基作用,及去脂减肥、降低血糖和胆固醇、预防心血管疾病、抑制肿瘤细胞等药理功能。现在市场上有以茶多糖为原料的药品,但未有由茶多酚和茶多糖(含部分小分子低聚糖)为主要成分的保健食品。本胶囊采用纯属天然茶多糖及茶多酚为主要活性成分,同时含有植物蛋白和微量元素,二者对人体也有益处。该胶囊无任何毒副作用,对降低血糖和血脂具有明显的作用,是一种不可多得的保健食品。
发明内容
本发明的目的是提供一种调节血糖、血脂保健品的组成及其制备方法。
它的组成为:茶多糖30%-65%、20%-30%茶多酚、5%-10%植物蛋白、10%-20%铁镁钙等微量元素。
制备方法为:取1000克下脚料粉末,用40-55度温水溶解,水的体积约为7000-8000ml。溶解后将糖液放入45度温度的水浴中加入1-5%量的果胶酶作用1.5-3.5小时,然后用3500-4000转速度离心去除不溶性物质,再向余液中加入3-6倍体积的氯仿搅拌萃取,静置30-40分钟后放出底部的氯仿层,剩余透明清亮的褐色溶液用真空干燥机干燥即得本保健品。以每颗0.25克灌入1号胶囊。
本保健品纯属天然制作,具有降低血糖、降血脂、提高人体免疫力、抗动脉粥样硬化、抗凝血、抗血栓的作用。还有抗菌、抗癌、抗衰老、抗紫外线和消除自由基作用及去脂减肥、降低血糖和胆固醇、预防心血管疾病、抑制肿瘤细胞等药理功能。本保健品配方合理,疗效高,药源丰富,制作成本低,易于推广应用。
具体实施方式
实施例1:
取1000克下脚料粉末,用55度温水溶解,水的体积约为8000ml。溶解后将糖液放入45度温度左右的水浴中加入3.5%量的果胶酶作用3.5小时,然后用4000转左右速度离心去除不溶性物质,再向余液中加入4.5倍体积的氯仿搅拌萃取,静置30分钟后放出底部的氯仿层,剩余透明清亮的褐色溶液用真空干燥机干燥即本保健品。再将此粉末以每颗0.25克的量灌装入1号胶囊。
实施例2:
取700克下脚料粉末,用55度温水溶解,水的体积约为5600ml。溶解后将糖液放入45度温度左右的水浴中加入3.0%量的果胶酶作用3.5小时,然后用4000转左右速度离心去除不溶性物质,再向余液中加入4.0倍体积的氯仿搅拌萃取,静置30分钟后放出底部的氯仿层,剩余透明清亮的褐色溶液用真空干燥机干燥即本保健品。再将此粉末以每颗0.25克的量灌装入1号胶囊。
实施例3:
取500克下脚料粉末,用55度温水溶解,水的体积约为4000ml。溶解后将糖液放入45度温度左右的水浴中加入2.5%量的果胶酶作用3.5小时,然后用4000转左右速度离心去除不溶性物质,再向余液中加入3倍体积的氯仿搅拌萃取,静置30分钟后放出底部的氯仿层,剩余透明清亮的褐色溶液用真空干燥机干燥即本保健品。再将此粉末以每颗0.25克的量灌装入1号胶囊。
本保健品经浙江省疾病预防控制中心检测结果如下:
(1)浙江省疾病预防控制中心检验报告书:浙(省)疾控检字第200205246号
本保健品由浙江大学生产并提供。供试样品为产品内容物,棕黄色粉末,实验时以蒸馏水作溶媒。实验按食品安全性毒理学评价程序要求,对该样品进行第一、二阶段毒性试验。
本保健品安全性毒理学评价试验:第一阶段大、小鼠急性经口毒性半数致死量(LD50),雌雄两性别均大于10.0g/kg体重,按急性毒性分级标准判定,该样品属实际无毒类;第二阶段Ames实验结果为阴性;小鼠骨髓细胞微核试验和小鼠***畸形试验结果为阴性。提示在本次实验条件下,该样品未显示有致突变性。大鼠喂养试验各项指标均未见明显毒性反应,其最大无作用剂量为1.67g/kg体重。
(2)浙江省疾病预防控制中心检验报告书:浙(省)疾控检字第200205182号
本保健品胶囊由浙江大学生物大分子和酶工程研究所生产并提供。供试样品为产品内容物,棕黄色粉末。实验按***《保健食品功能学评价程序和检验方法》进行。
本次实验,设低、中、高三个剂量组,分别相当于人实际摄入量的5、10、30倍。实验结果表明:与高脂对照组大鼠相比,高、中、低剂量组均能明显降低高脂血症大鼠血清胆固醇(TC)和血情甘油三酯(TG)含量。
结论:本保健食品胶囊具有调节血脂作用。
(3)浙江省疾病预防控制中心检验报告书:浙(省)疾控检字第200204964号
本保健品胶囊由浙江大学生物大分子和酶工程研究所生产并提供。样品为棕黄色粉末,实验时以蒸馏水为溶媒。实验按***《保健食品功能学评价程序和检验方法》(讨论稿)1999进行。
本次实验分正常动物和高血糖模型动物两批进行,各设1个对照组(蒸馏水)和低、中、高三个受试物剂量组,分别相当于人推荐摄入量的5、10、30倍,连续三十天经口给予相应剂量的受试物。结果表明:与模型对照组比较,受试物高剂量组能明显降低高血糖模型小鼠的空腹血糖和餐后血糖值(q检验,p<0.05)。
结论:本保健食品胶囊具有调节血糖作用。
Claims (2)
1.一种调节血糖、血脂保健食品的组成,其特征在于它的组成为:茶叶粗多糖30%-65%、20%-30%茶多酚、5%-10%植物蛋白、10%-20%铁镁钙等微量元素。
2.一种调节血糖、血脂保健食品的制备方法,其特征:取1000克下脚料粉末,用40-55度温水溶解,水的体积约为7000-8000ml。溶解后将糖液放入45度温度的水浴中加入1-5%量的果胶酶作用1.5-3.5小时,然后用3500-4000转速度离心去除不溶性物质,再向余液中加入3-6倍体积的氯仿搅拌萃取,静置30-40分钟后放出底部的氯仿层,剩余透明清亮的褐色溶液用真空干燥机干燥,采用硬胶囊包装即得本保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03114899 CN1431016A (zh) | 2003-01-13 | 2003-01-13 | 调节血糖、血脂保健食品的组成及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03114899 CN1431016A (zh) | 2003-01-13 | 2003-01-13 | 调节血糖、血脂保健食品的组成及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1431016A true CN1431016A (zh) | 2003-07-23 |
Family
ID=4790522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03114899 Pending CN1431016A (zh) | 2003-01-13 | 2003-01-13 | 调节血糖、血脂保健食品的组成及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1431016A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101213997B (zh) * | 2008-01-04 | 2011-07-27 | 上海师范大学 | 一种休闲保健茶饮料及其制备方法 |
CN104799391A (zh) * | 2015-04-28 | 2015-07-29 | 天津科技大学 | 一种乌龙茶茶多糖复合型减肥固体饮料和应用 |
CN108498486A (zh) * | 2018-07-02 | 2018-09-07 | 天津大学 | 一种bsa-egcg-tps纳米颗粒的制备方法 |
CN114794487A (zh) * | 2021-01-22 | 2022-07-29 | 中国科学院上海营养与健康研究所 | 一种治疗糖尿病的方法 |
-
2003
- 2003-01-13 CN CN 03114899 patent/CN1431016A/zh active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101213997B (zh) * | 2008-01-04 | 2011-07-27 | 上海师范大学 | 一种休闲保健茶饮料及其制备方法 |
CN104799391A (zh) * | 2015-04-28 | 2015-07-29 | 天津科技大学 | 一种乌龙茶茶多糖复合型减肥固体饮料和应用 |
CN108498486A (zh) * | 2018-07-02 | 2018-09-07 | 天津大学 | 一种bsa-egcg-tps纳米颗粒的制备方法 |
CN114794487A (zh) * | 2021-01-22 | 2022-07-29 | 中国科学院上海营养与健康研究所 | 一种治疗糖尿病的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ru et al. | Synthesis of selenylated polysaccharides from Momordica charantia L. and its hypoglycemic activity in streptozotocin-induced diabetic mice | |
BRPI0708825A2 (pt) | extratos e mÉtodos que compreendem espÉcies de ganoderma | |
CN1742763A (zh) | 五层龙提取物在制备保健品和药品中的应用 | |
CN108379305A (zh) | 桑黄水提物在抗尿酸中的应用 | |
CN1330670C (zh) | 玉竹多糖的提取方法、药物制剂制备方法及其用途 | |
Chen et al. | Anticancer activity of rhamnoallosan against DU-145 cells is kinetically complementary to coexisting polyphenolics in Psidium guajava budding leaves | |
RU2695224C2 (ru) | Фармацевтическая комбинация, содержащая силибин | |
Inngjerdingen et al. | Chemical and biological characterization of polysaccharides from wild and cultivated roots of Vernonia kotschyana | |
CN1434053A (zh) | 知母提取物及其制备方法和用途 | |
CN1931874B (zh) | 人参糖肽的制备方法、药物制剂及医药用途 | |
CN106943372A (zh) | 一种辅助降血糖软胶囊及其生产工艺 | |
Mukhtar et al. | Effect of aqueous extract of Cyamopsis tetragonoloba Linn. beans on blood glucose level in normal and alloxan-induced diabetic rats | |
CN1431016A (zh) | 调节血糖、血脂保健食品的组成及其制备方法 | |
CN111166820B (zh) | 一种含佛手的中药组合物及制剂和用途 | |
CN106822166B (zh) | 一种防治糖尿病和高脂血症的药物及其在制药中的应用 | |
KR100979459B1 (ko) | 근육세포에서 포도당 흡수를 증가시키는 데이츄 추출물과이로부터 분리한 4h-크로멘-4-온 유도체 | |
JP2021512997A (ja) | 分離された防風多糖及びその用途 | |
CN101972284B (zh) | 松针脂溶性提取物的制备方法及其在制备治疗胃溃疡药物中的应用 | |
CN102526198A (zh) | 一种以肉桂和铬为添加剂的药品及保健品的制备方法 | |
CN105902601B (zh) | 酸角壳提取物在制备降血脂药物中的应用 | |
CN1163228C (zh) | 茶多酚及其氧化物治疗肌肉疾病的新用途 | |
Sudipta et al. | Evaluation of antidiabetic activity and histological study of Cyperus kyllinga Endl. roots | |
KR100447668B1 (ko) | 불용성 생리활성물질을 함유한 분산성 조각 젤리타입입자혼입 기능성음료 제조방법 | |
KR0173814B1 (ko) | 해당화 근부 추출물을 포함하는 건강보조식품 | |
CN103768294A (zh) | 紫芋及其茎叶在预防治疗糖尿病中的医用用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |